MOURI Atsuto 毛利篤人

… Alternative Names

mouri atsuto 毛利篤人

Less

Researcher Number	20774657
Other IDs
Affiliation (Current)	2025: 埼玉医科大学, 医学部, 准教授 2025: 独立行政法人国立病院機構災害医療センター(臨床研究部), その他部局等, 研究員(移行)
Affiliation (based on the past Project Information) *help	2017 – 2018: 埼玉医科大学, 医学部, 助教
Review Section/Research Field	Principal Investigator Respiratory organ internal medicine
Keywords	Principal Investigator 免疫療法 / 非小細胞性肺癌 / アルゴリズム / 拡大 / 投与間隔 / 免疫チェックポイント / 免疫阻害薬 / ニボルマブ / 治療奏功例 / 休薬 … More / 投与中止 / 免疫関連有害事象 / 切除不能進行期非小細胞性肺癌 / 治療奏効例 / 免疫チェックポイント阻害薬 Less

Development of algorithm to enlarge dose interval with Nivolumab for patients with Non-small cell lung carcinomaPrincipal Investigator
- Principal Investigator
  
  mouri atsuto
- Project Period (FY)
  2017 – 2018
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Respiratory organ internal medicine
- Research Institution
  Saitama Medical University

All 2019 2018 2017

All Journal Article Presentation

[Journal Article] Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients2019
- Author(s)
  Shiono Ayako、Kaira Kyoichi、Mouri Atsuto、Yamaguchi Ou、Hashimoto Kosuke、Uchida Takahiro、Miura Yu、Nishihara Fuyumi、Murayama Yoshitake、Kobayashi Kunihiko、Kagamu Hiroshi
- Journal Title
  
  Thoracic Cancer
  
  Volume: 10 Issue: 4 Pages: 775-781
- DOI
  10.1111/1759-7714.12998
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17H04184, KAKENHI-PROJECT-17K16058, KAKENHI-PROJECT-17K09665
[Journal Article] Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab2019
- Author(s)
  Yamaguchi Ou、Kaira Kyoichi、Hashimoto Kosuke、Mouri Atsuto、Miura Yu、Shiono Ayako、Nishihara Fuyumi、Murayama Yoshitake、Noda Shin‐ei、Kato Shingo、Kobayashi Kunihiko、Kagamu Hiroshi
- Journal Title
  
  Thoracic Cancer
  
  Volume: 10 Issue: 4 Pages: 992-1000
- DOI
  10.1111/1759-7714.13044
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17H04184, KAKENHI-PROJECT-17K16058, KAKENHI-PROJECT-17K09665
[Journal Article] Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.2019
- Author(s)
  Mouri A, Kaira K, Shiono A, Yamaguchi O, Murayama Y, Kobayashi K, Kagamu H.
- Journal Title
  
  Thorac Cancer.
  
  Volume: 10 Issue: 4 Pages: 1005-1008
- DOI
  10.1111/1759-7714.13022
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K16058
[Journal Article] Combination Therapy with Carboplatin and Paclitaxel for Small Cell Lung Cancer2019
- Author(s)
  Atsuto Mouri, Ou Yamaguchi, Sachiko Miyauchi, Ayako Shiono, Harue Utsugi, Fuyumi Nishihara, Yoshitake Murayama, Hiroshi Kagamu, Kunihiko Kobayashi
- Journal Title
  
  Respiratory investigation
  
  Volume: 57 Issue: 1 Pages: 34-39
- DOI
  10.1016/j.resinv.2018.09.004
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K16058, KAKENHI-PROJECT-17K09665
[Journal Article] Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.2019
- Author(s)
  Yamaguchi O, Kaira K, Mouri A, Shiono A, Hashimoto K, Miura Y, Nishihara F, Murayama Y, Kobayashi K, Kagamu H.
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 83 Issue: 5 Pages: 817-825
- DOI
  10.1007/s00280-019-03790-w
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-17K16058
[Presentation] CD4+T-cell immunity correlates with long-lasting antitumor immunity after PD-1 blockade therapy2019
- Author(s)
  解良　恭一、毛利　篤人、山口央、橋本康佑、三浦雄、内田貴裕、塩野文子、西原冬実、村山芳武、小林国彦、各務博
- Organizer
  American Society Clinical Oncology Annual Meeting
- Int'l Joint Research
- Data Source
  KAKENHI-PROJECT-17K16058
[Presentation] 当院におけるNivolumab投与有効症例における有害事象発症後についての検討2018
- Author(s)
  毛利篤人、山口央、橋本康佑、三浦雄、内田貴裕、塩野文子、西原冬実、村山芳武、解良恭一、小林国彦、各務博
- Organizer
  日本肺癌学会
- Data Source
  KAKENHI-PROJECT-17K16058
[Presentation] 当院におけるラムシルマブ使用症例について検討2018
- Author(s)
  塩野文子、毛利　篤人、山口央、橋本康佑、三浦雄、内田貴裕、西原冬実、村山芳武、小林国彦、解良　恭一、各務博
- Organizer
  日本臨床腫瘍学会
- Data Source
  KAKENHI-PROJECT-17K16058
[Presentation] Progression-free duration of NSCLC patients after cessation of Nivolumab2017
- Author(s)
  毛利　篤人
- Organizer
  日本臨床腫瘍学会
- Data Source
  KAKENHI-PROJECT-17K16058

1. 各務博

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results
2. 小林国彦

# of Collaborated Projects: 0 results

# of Collaborated Products: 2 results

MOURI Atsuto 毛利 篤人

mouri atsuto 毛利 篤人

Research Projects

Research Products

Co-Researchers

Development of algorithm to enlarge dose interval with Nivolumab for patients with Non-small cell lung carcinomaPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Clinical significance of primary prophylactic pegylated-granulocyte-colony stimulating factor after the administration of ramucirumab plus docetaxel in patients with previously treated non-small cell lung cancer.2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Combination Therapy with Carboplatin and Paclitaxel for Small Cell Lung Cancer2019

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation.2019

Author(s)

Journal Title

DOI

Data Source

[Presentation] CD4+T-cell immunity correlates with long-lasting antitumor immunity after PD-1 blockade therapy2019

Author(s)

Organizer

Data Source

[Presentation] 当院におけるNivolumab投与有効症例における有害事象発症後についての検討2018

Author(s)

Organizer

Data Source

[Presentation] 当院におけるラムシルマブ使用症例について検討2018

Author(s)

Organizer

Data Source

[Presentation] Progression-free duration of NSCLC patients after cessation of Nivolumab2017

Author(s)

Organizer

Data Source

MOURI Atsuto 毛利篤人

mouri atsuto 毛利篤人